NovalGen to collaborate with CRUK to progress NVG-222 into a Phase I clinical study
10th December 2023
NovalGen presents NVG-111 clinical data in hematological malignancies in an oral session and preclinical data for next-generation AR T cell engager NVG-222 at the 65th American Society of Hematology Annual Meeting
